

First reports of adverse drug reactions

Accepted: 4 April 2022
© Springer Nature Switzerland AG 2022

Table 1 contains an overview of first published case reports of adverse drug reactions and interactions identified in the international literature in recent weeks by *Reactions Weekly*, the Adis drug safety newsletter. *Reactions Weekly* provides summaries of adverse drug reaction news sourced from journals,

scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme.

Table 1 First reports of adverse drug reactions

Drug: adverse reaction (all serious)	Reference
Adalimumab + azathioprine: Kikuchi-Fujimoto disease	Shaikh DH, et al. First reported case of Kikuchi-Fujimoto disease in a Crohn's disease patient [abstract no. S2397]. <i>Am J Gastroenterol.</i> 2021;116(Suppl.):S1017
Azelnidipine: complete atrioventricular block	Ide N, et al. A case of complete atrioventricular block with extremely high blood concentration of azelnidipine. <i>J Pharm Health Care Sci.</i> 2021;7(1):48
Bevacizumab: oesophageal pleural fistula	Wang T, et al. Bevacizumab-induced esophageal pleural fistula during maintenance therapy without radiation in lung cancer. <i>BMC Pulm Med.</i> 2021;21(1):384
Blinatumomab: pneumatoses intestinalis	Kim SE, et al. Blinatumomab-related pneumatoses intestinalis in a pediatric patient with relapsed acute lymphoblastic leukemia: a case report. <i>J Oncol Pharm Pract.</i> 2021;27(8):2045-8
Capecitabine: acute oesophageal necrosis	Muzahim YE, et al. Acute esophageal necrosis: patient with a history of liver cancer on capecitabine [abstract no. S2088]. <i>Am J Gastroenterol.</i> 2021;116(Suppl.):S901
Durvalumab: minimal change disease	Toda MG, et al. Minimal change disease associated with durvalumab. <i>Kidney Int Rep.</i> 2021;6(10):2733-4
Dydrogesterone: Takotsubo cardiomyopathy	Ioannou A. Takotsubo cardiomyopathy associated with dydrogesterone use. <i>BMJ Case Rep.</i> 2021;14(11):e246553
Guselkumab: bullous pemphigoid	Burlando M, et al. Guselkumab-associated bullous pemphigoid in a psoriasis patient: a case report and review of the literature. <i>Dermatol Ther.</i> 2022;35(1):e15207
Lidocaine + propofol: extravasation pain masking	Zhong G, et al. Propofol extravasation pain masked by lignocaine premedication. <i>Korean J Anesthesiol.</i> 2021;74(4):366-7
Metamfetamine: sensorineural hearing loss	Reich JS, et al. Bilateral sensorineural hearing loss in the setting of acute methamphetamine overdose. <i>Ear Nose Throat J.</i> 2021. doi: 10.1177/01455613211069353
Oxford AstraZeneca COVID-19 vaccine (AZD-1222): linear IgA bullous dermatosis	Hali F, et al. Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine. <i>Clin Exp Dermatol.</i> 2022;47(3):611-3
Tadalafil: paracentral acute middle maculopathy	Sebastiani S, et al. Paracentral acute middle maculopathy associated with phosphodiesterase-5 inhibitor therapy. <i>Retin Cases Brief Rep.</i> 2021;15(5):519-22
Tozinameran: rhombencephalitis	Walter A, et al. A neurologist's rhombencephalitis after comirnaty vaccination. A change of perspective. <i>Neurol Res Pract.</i> 2021;3(1):56
Treprostinil: haemorrhagic cholecystitis	Song K, et al. Hemobilia and hemorrhagic cholecystitis caused by systemic vasodilator therapy for pulmonary arterial hypertension [abstract no. S2353]. <i>Am J Gastroenterol.</i> 2021;116(Suppl.):S1001

An event is serious (US FDA MedWatch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment or damage